Kerui Wu
Overview
Explore the profile of Kerui Wu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
Deshpande R, Wu K, Wu S, Tyagi A, Smith E, Kim J, et al.
EMBO Mol Med
. 2025 Mar;
PMID: 40087501
We aimed to restore MHC-I expression on the surface of solid tumors including breast cancer and melanoma cells to regain sensitivity to immunotherapy and suppress metastatic progression. We screened a...
2.
Tyagi A, Wu S, Sharma S, Wu K, Zhao D, Deshpande R, et al.
Oncogene
. 2025 Jan;
44(5):339.
PMID: 39789166
No abstract available.
3.
Sharma S, Wu S, Jimenez H, Xing F, Zhu D, Liu Y, et al.
EBioMedicine
. 2024 Dec;
111():105541.
PMID: 39731855
No abstract available.
4.
Zhao D, Deshpande R, Wu K, Tyagi A, Sharma S, Wu S, et al.
Neoplasia
. 2024 Dec;
60:101100.
PMID: 39671912
Recent development of immune checkpoint inhibitors has revolutionized cancer immunotherapy. Although these drugs show dramatic effects on a subset of cancer patients, many other tumors are non-responsive and the pathological...
5.
Sharma S, Pei X, Xing F, Wu S, Wu K, Tyagi A, et al.
Oncogene
. 2024 Nov;
44(4):271.
PMID: 39528817
No abstract available.
6.
Tumor-intrinsic CDC42BPB confers resistance to anti-PD-1 immune checkpoint blockade in breast cancer
Deshpande R, Wu K, Wu S, Tyagi A, Smith E, Hunting J, et al.
Mol Ther
. 2024 Aug;
32(10):3669-3682.
PMID: 39086134
Immune checkpoint blockade has been used to treat breast cancer, but the clinical responses remain relatively poor. We have used the CRISPR-Cas9 kinome knockout library consisting of 763 kinase genes...
7.
Wang J, Wu C, Wang Y, Shen Y, Wu K, Shi Y, et al.
Biomaterials
. 2024 Jul;
311:122710.
PMID: 39053036
Low-expression antigens, especially neoantigens, pose a significant challenge in immunotherapy for low immunogenicity pancreatic cancer. Increasing the tumor mutation burden is crucial to enhance the expression of tumor antigens and...
8.
Liu Y, Yalavarthi S, Yang F, Abdul-Rashid Y, Tang S, Long Z, et al.
BMC Pulm Med
. 2024 Jul;
24(1):309.
PMID: 38956553
Background: Treatment of non-small lung cancer (NSCLC) has evolved in recent years, benefiting from advances in immunotherapy and targeted therapy. However, limited biomarkers exist to assist clinicians and patients in...
9.
Lyu F, Wu K, Wu S, Deshpande R, Tyagi A, Ruiz I, et al.
Oncogene
. 2023 Nov;
43(5):319-327.
PMID: 38030790
Dendritic cells (DCs) play critical roles in recognizing and presenting antigens to T cells. They secrete dendritic cell-derived extracellular vesicles (DC-sEVs), which could mimic the function of DCs. Therefore, we...
10.
Wu K, Lyu F, Wu S, Sharma S, Deshpande R, Tyagi A, et al.
Sci Adv
. 2023 May;
9(17):eade0625.
PMID: 37126558
Breast cancer has been shown to be resistant to immunotherapies. To overcome this challenge, we developed an active immunotherapy for personalized treatment based on a smart nanovesicle. This is achieved...